As with other potent immunosuppressive compounds, the risk of secondary cancer is unknown (see section 4.8).
Nagu ka teiste tugevatoimeliste immunosupressiivsete ravimite puhul, on teisese vähi risk teadmata (vt lõik 4. 8).